Rationale: Low-dose acetylsalicylic acid (aspirin) is widely used in the treatment and prevention of vascular atherothrombosis. Cardiovascular doses of aspirin also reduce systemic blood pressure and improve endotheliumdependent vasorelaxation in patients with atherosclerosis or risk factors for atherosclerosis. Aspirin can acetylate proteins, other than its pharmacological target cyclooxygenase, at lysine residues. The role of lysine acetylation in mediating the effects of low-dose aspirin on the endothelium is not known.
L ow-dose aspirin (81 to 325 mg/d) is a very useful tool in the armamentarium for the treatment of acute coronary syndromes, as well as for the secondary prevention of myocardial infarctions and stroke in high-risk patients. 1 The antithrombotic effects of low-dose aspirin are principally attributed to acetylation of a serine residue in platelet cyclooxygenase (COX)-1, irreversibly inhibiting COX-1 in platelets, and limiting platelet aggregation because of prostanoids produced by COX-1. 2 In addition to preventing thrombosis, low-dose aspirin also improves vasomotor function mediated by the endothelium in humans 3, 4 and in animal models of endothelial dysfunction. 5 Although low-dose aspirin is not commonly used in the treatment of hypertension, it is efficacious, when given at bedtime, for reduction of blood pressure in individuals with mild hypertension 6, 7 or prehypertension. 8 Suppression of vasoconstricting prostanoids produced by COX-1 could be one mechanism by which low-dose aspirin improves endothelial function and reduces mildly and bor-derline elevated blood pressure. Notably, acetylation of alternate vasoregulatory targets by aspirin, other than COX-1, by aspirin could provide alternative explanations for its vasoprotective effects.
Low-dose aspirin increases NO produced by blood vessels, 9 but the mechanism responsible for this effect is not fully understood. Cardiovascular doses of aspirin increase nitric oxide synthase (NOS) enzymatic activity in endothelial cell homogenates 9 and in platelets, 10 and aspirin at high concentrations acetylates endothelial (e)NOS serine residues. 10 Aspirin also acetylates lysine residues in other target proteins including hemoglobin 11, 12 and ubiquitin. 13 However, unlike serine acetylation, lysine acetylation of biologically relevant cardiovascular targets by low-dose aspirin, and the physiological significance of such acetylation has not been reported. Therefore, we asked whether cardiovascular doses of aspirin acetylate the ⑀ amino groups of lysine residues in eNOS and investigated the physiological relevance of this chemical modification on eNOS-derived NO production. Moreover, reasoning that lysine acetylation in many proteins is reversible by endogenous lysine deacetylases, we explored the role of such deacetylases in antagonizing the effects of low-dose aspirin on lysine acetylation of eNOS, and endothelial NO production.
Methods
An expanded Methods section detailing the materials, methods, and statistics implemented in this study is available in the Online Data Supplement at http://circres.ahajournals.org.
Endothelial NOS Ϫ/Ϫ mice in a C57BL/6J background were purchased from The Jackson Laboratory. The C57BL/6J strain was used as a wild-type control strain. Mice were administered aspirin or salicylic acid (3 mg/kg) intravenously or by gastric gavage and euthanized after 45 to 60 minutes. The COX-1 inhibitor sc-560 (Cayman Chemicals) or vehicle control was injected intraperitoneally at 20 mg/kg 30 minutes before administration of aspirin or salicylic acid. All animals were treated in accordance with protocols approved by the Institutional Animal Care and Use Committee.
Results and Discussion
We first determined whether eNOS is a target of lysine acetylation by low-dose aspirin. Within a concentration range that is acutely achieved in human plasma with oral administration of a 100-mg cardiovascular dose, 14 aspirin rapidly and concentration-dependently acetylated eNOS expressed in HEK 293 cells ( Figure 1A and 1B) . A similar increase in lysine acetylation of endogenous eNOS in human umbilical vein endothelial cells (HUVECs) was observed with low concentrations of aspirin ( Figure 1C ). In parallel with the increase in lysine acetylation of eNOS, aspirin at low concentrations stimulated metabolites derived from NO produced by eNOS expressed in HEK 293 cells ( Figure 1D ), and by HUVECs ( Figure 1E ). In addition, low concentration of aspirin stimulated enzymatic activity of eNOS expressed in HEK 293 cells ( Figure  1F ). Because COX-1, a known target of low-dose aspirin, is constitutively expressed in many cells including endothelial cells, 15 we then asked whether aspirin-stimulated NO in endothelial cells is dependent on COX-1. Knockdown of constitutive COX-1 expression with small interfering (si)RNA resulted in an increase in eNOS expression, but did not inhibit low-dose aspirin-stimulated NO production ( Figure 1G ). Similarly, treatment of HUVECs with sc-560, a COX-1 selective inhibitor, 16 did not abolish aspirin-stimulated NO (Online Figure II) . This reveals that clinically relevant concentrations of aspirin acetylate lysine residues of endogenous and ectopically expressed eNOS in cultured cells and suggests that acetylation mediates increased eNOS catalytic activity and NO production. Furthermore, this implicates a COX-1-independent mechanism for aspirin modulation of endothelial NO production.
We then asked whether eNOS is a direct target of lysine acetylation by aspirin. Aspirin acetylated recombinant eNOS on lysine residues in vitro ( Figure 2A ). Moreover, aspirin promoted the enzymatic activity of recombinant eNOS ( Figure 2B ). Increase in lysine acetylation and activation of recombinant eNOS was first evident at high micromolar concentrations, approximating the reported IC 50 of aspirin for recombinant COX-1. 17 However, to achieve a maximal effect on eNOS activity and lysine acetylation, millimolar concentrations of aspirin were required. The higher concentrations of aspirin required to achieve maximal lysine acetylation and activation of recombinant eNOS, when compared with eNOS expressed in cells, indicates that aspirin is a better acetylator of ⑀ amino groups in vivo than in vitro. Such concentrations of aspirin are also required for in vitro lysine acetylation of other known target proteins, including hemoglobin 11 and ubiquitin. 13 The relative insensitivity of recombinant eNOS to aspirin may also be reflective of the fact that mechanisms that stimulate and are required for optimal eNOS activity, such as phosphorylation by Akt kinase 18 and binding to hsp90, 19 are present in intact cells but not in vitro. These findings show that eNOS is directly acetylated on lysine residues by aspirin, and this acetylation stimulates its enzymatic activity. Next, we examined the role of specific lysine residues in modulating NO production by low-dose aspirin. Lysine acetylation of ubiquitin by aspirin occurs by a transacetylation process in which a histidine residue, in proximity to the target lysine, is first acetylated by aspirin, and this acetylated histidine intermediate then transfers the acetyl group to the lysine residue. 13 The occurrence of histidine in the catalytic microenvironment has been similarly proposed to play an important role in formation of lysine glycation adducts of alcohol dehydrogenase. 20 Hypothesizing a similar catalytic role for histidine in facilitating the reactivity of lysine residues in eNOS to aspirin, we targeted lysines in proximity to histidine residues. Within bovine eNOS exists a single tandem histidine-lysine pair at position 608 to 609 (corresponding to positions 606 to 607 in human eNOS). This histidine-lysine pair is in the calmodulin autoinhibitory domain of eNOS, and is conserved across species ( Figure  2C ). We mutated lysine 609 to nonacetylatable arginine (eNOS [K609R]), and compared the stimulatory effect of low concentrations of aspirin on wild-type eNOS and eNOS (K609R). NO produced by eNOS (K609R) under resting conditions was similar to that of wild-type protein ( Figure  2D ). However, in contrast to its effect on wild-type eNOS aspirin did not stimulate NO produced by eNOS (K609R) ( Figure 2D ). Moreover, unlike wild-type eNOS, lysine acetylation of eNOS (K609R) was not stimulated by aspirin ( Figure 2E ). In addition to lysine 609, we also targeted other conserved lysine residues in the calmodulin autoinhibitory domain of eNOS. Because lysines 631 and 633 are in proximity to serine 635, phosphorylation of which stimulates eNOS activity, 21 we asked whether acetylation of these lysine residues, by mimicking phosphorylation of serine 635, could mediate aspirin-stimulated NO production. However, similar to its effect on NO produced by wild-type eNOS, aspirin stimulated NO production by the acetylation-resistant eNOS (K631/633R) ( Figure 2F ). In addition, unlike the lack of effect of aspirin on lysine acetylation of eNOS (K609R), low concentrations of aspirin increased lysine acetylation of eNOS (K631/633R) ( Figure 2G ). Thus, aspirin stimulates eNOS-derived NO production by targeting specific lysine residues in the calmodulin autoinhibitory domain of eNOS for acetylation.
Non-standard Abbreviations and Acronyms
Sirtuin (SIRT)1 is a class III histone deacetylase. It targets many nonhistone proteins including eNOS, stimulating eNOS activity by deacetylating lysines in its calmodulin-binding domain. 22 Although K609 is not in the calmodulin-binding domain, we nevertheless questioned whether SIRT1 plays any part in the regulation of eNOS-derived NO stimulated by low-dose aspirin. SIRT1 overexpression increased NO derived from both WT and K609R eNOS to the same extent ( Figure 2H ), indicating that lysine 609, which mediates aspirin-stimulated NO, is not a target of SIRT1.
The autoinhibitory domain of eNOS inhibits its activation by interfering with its binding to calmodulin. 23 Because lysine 609 is in the autoinhibitory domain of eNOS, we hypothesized that its acetylation mediates aspirin-stimulated eNOS activation by promoting binding of eNOS to calmodulin. To investigate this possibility, we first examined the effect of low concentrations of aspirin on binding of calmodulin to eNOS. Aspirin rapidly stimulated the binding of eNOS and calmodulin expressed in HEK 293 cells ( Figure 3A and 3B) . A similar increase in the binding of endogenous eNOS to endogenous calmodulin was observed in endothelial cells exposed to aspirin ( Figure 3C ). In contrast, aspirin had no effect on binding of calmodulin to eNOS that is nonacetylatable on lysine 609 (K609R) ( Figure 3D ). These findings indicate that cardiovascular concentrations of aspirin stimulate eNOS activity by promoting its binding to calmodulin, and demonstrate the importance of lysine 609 in mediating aspirin-stimulated binding of eNOS to calmodulin.
Serine acetylation of platelet COX-1 by cardiovascular doses of aspirin is nonreversible and may reflect the limited complement of cellular proteins found in nonnucleated platelets. In nucleated cells, acetylation of lysines is a reversible posttranslational modification. Histone deacetylases (HDACs) remove acetyl residues from ⑀ amino-acetylated lysines in histones and nonhistone proteins, thereby modifying protein structure and function. 24 We therefore asked whether lysine acetylation of eNOS is reversible by HDAC. Because eNOS is a cytosolic protein, we limited our search to HDAC that are expressed in the cytoplasm. HDAC3 belongs to class I HDAC and is expressed both in the nucleus and cytoplasm. 25, 26 In keeping with its presence in the cytoplasm, several nonhistone substrates of HDAC3 have been identified. [27] [28] [29] In endothelial cells, HDAC3 mediates a prothrombotic and proinflammatory phenotype. 30, 31 We therefore focused our attention on HDAC3 as a potential endogenous antagonist to aspirin-stimulated lysine acetylation of eNOS. We first asked whether HDAC3 and eNOS associate with each other. HDAC3 and eNOS expressed in HEK 293 cells coimmunoprecipitated with each other ( Figure 4A ). Endogenous HDAC3 and eNOS also coimmunoprecipitated in endothelial cells, and this association was stimulated by aspirin ( Figure 4B ). We next determined whether HDAC3 antagonizes aspirin-induced lysine acetylation of eNOS. Overexpression of HDAC3 in HEK293 cells abrogated the increase in lysine acetylation of eNOS ( Figure 4C ), and eNOS-derived NO ( Figure 4D ) stimulated by low concentrations of aspirin. Unlike HDAC3, the SIRT1 lysine deacetylase, which also binds to and deacetylates eNOS, 22 did not inhibit aspirinstimulated NO ( Figure 4E ). Conversely, knockdown of endogenous HDAC3 in endothelial cells increased lysine acetylation of endogenous eNOS, without affecting eNOS expression ( Figure 4F ). The increase in lysine acetylation of eNOS corresponded with an increase in NO produced by endothelial cells in which HDAC3 was knocked down (Figure 4G) . Importantly, recombinant active HDAC3 suppressed lysine acetylation of recombinant eNOS by aspirin in vitro ( Figure 4G ), and decreased aspirin-stimulated eNOS enzymatic activity ( Figure 4I ). Because aspirin led to an increase in binding of eNOS to calmodulin ( Figure 4A through 4C) , we then asked whether HDAC3 modulates this binding. Aspirin-stimulated binding of eNOS to calmodulin was negated by overexpression of HDAC3 ( Figure 4J ). These findings show that HDAC3 targets lysine-acetylated eNOS for deacetylation, thereby antagonizing aspirin-stimulated binding of eNOS to calmodulin, and inhibiting aspirintriggered increase in eNOS activity and NO production. The increase in resting lysine acetylation of eNOS and NO in endothelial cells with knockdown of HDAC3, independent of aspirin, also hints at the presence of an endogenous lysine acetyltransferase that targets eNOS for acetylation.
We next ascertained the role of eNOS in mediating the physiological effects of low-dose aspirin on the vasculature. Mice were administered a cardiovascular dose of aspirin intravenously or by gastric gavage, followed by measurements of eNOS acetylation, serum NO, and vascular bioavailable NO. A 3 mg/kg dose (corresponding to 300 mg given to an adult human) of aspirin given IV or by gastric gavage increased aortic bioavailable NO ( Figure 5A ), and serum NO (Figure 5B ), respectively. The increase in serum and aortic bioavailable NO was accompanied by an increase in lysine acetylation of eNOS in hepatic tissue ( Figure 5C and 5D) . Importantly, aspirin did not increase aortic bioavailable NO in mice genetically deficient for eNOS (eNOSϪ/Ϫ) ( Figure  5A ). Because low-dose aspirin inhibits platelet COX-1 in vivo, we also determined the role of aspirin-induced COX-1 inhibition in mediating the increase in bioavailable vascular NO. Sc-560, the selective pharmacological inhibitor of COX-1, was delivered in vivo at a dose that inhibits COX-1-derived prostanoids. 32 When compared with salicylic acid, low-dose aspirin led to an increase in bioavailable NO in aortas of mice pretreated with sc-560 just as it did in mice not treated with sc-560 ( Figure 5E ). The lack of effect of COX-1 inhibition on aspirin-stimulated increase in vascular NO bioavailability was evident at all concentrations of phenylephrine ( Figure 5F ). These findings indicate that a cardiovascular dose of aspirin administered in vivo, via oral or parenteral route, promotes lysine acetylation of eNOS, and acutely increases vascular NO levels in a COX-1-independent, eNOS-dependent fashion.
Antiinflammatory concentrations of aspirin acetylate eNOS on serines 765 and 771 (767 and 773 in bovine eNOS). 10 The functional significance of serine acetylation in regulating eNOS has not been reported. Therefore, we examined the importance of these serine residues by measuring aspirin-stimulated NO produced by eNOS that is nonacetylatable on these residues (eNOS S767/773R). Low-dose aspirin increased NO derived from eNOS (S767/ 773R), although the magnitude of increase was smaller when compared with WT eNOS (Online Figure VI) . Thus, acetylation of these serine residues by low-dose aspirin may play an important part in mediating the effects of aspirin on the endothelium. However, acetylation of these serine residues cannot fully account for aspirin's stimulatory effect on eNOS.
Our work did not explore the effect of aspirin on endothelial NO in the context of vascular inflammation. It is known, however, that inducible NOS and eNOS mediate the antiinflammatory effects of high-dose aspirin, and this has been attributed to aspirin-triggered epi-lipoxin generation in inflamed tissues. 33 In the inflammatory milieu, aspirin acetylates the active site of cycloxygenase-2 (COX-2) in endothelial or epithelial cells resulting in conversion of arachidonic acid to the intermediary (15R) hydroxyeicosatetraenoic acid which is rapidly metabolized in a transcellular fashion by lipoxygenases in leukocytes to epi-lipoxins. 34 Moreover, aspirin modulates COX-2 activity to generate omega-3 fatty acid derivatives such as docosahexanoic acid, 35 which increases eNOS activity. 36, 37 COX-2 can be induced in endothelial cells, 15 and is upregulated in blood vessels of individuals with cardiovascular risk factors. 38 Thus, the effect of aspirin on endothelial NO production during vascular inflammation may also be dependent on COX-2 and be mediated by aspirintriggered epi-lipoxins and keto-fatty acid derivatives.
Aspirin is not a potent vasodilator but does reduce systemic blood pressure in mild hypertension and prehypertension. 6, 8 This effect is consistent with observations that low-dose aspirin stimulates production of endothelial NO to a much lesser degree than vasodilators such as acetylcholine and bradykinin. 9, 39, 40 In line with these observations, low-dose aspirin, when used alone, does not lead to vasodilation of preconstricted vascular rings. 9 One limitation of our work is that we did not examine the effect of aspirin on vascular tone in vivo in a model of hypertension. However, we expect low-dose aspirin to have a small impact, at best, on blood pressure in vivo. Despite this, low-dose aspirin is efficacious in improving vascular relaxation and endothelial function in the setting of endothelial dysfunction, such as seen with aging and hypercholesterolemia. 4, 5 In such settings where endothelial NO production is decreased, the increase in vascular NO stimulated by aspirin, albeit modest, may be sufficient to elicit an effect on vascular tone.
Lysine acetylation/deacetylation has recently been recognized as a novel posttranslational mechanism for the regulation of eNOS activity. The class III HDAC SIRT1 deacetylates and activates eNOS, and this activation is mediated by lysine residues in the calmodulin-binding domain of eNOS. 22 The role of class I HDAC (to which HDAC3 belongs) and class II HDAC in targeting eNOS for deacetylation has hitherto not been reported. The stimulatory effect of SIRT1-mediated deacetylation of lysine residues in the calmodulinbinding domain, compared with the inhibitory role of HDAC3-mediated deacetylation of a lysine residue in the calmodulin autoinhibitory domain, speaks to a finely tuned acetylation-deacetylation mechanism for the regulation of eNOS enzymatic activity.
We did not observe a significant change in eNOS expression with knockdown of HDAC3 in endothelial cells. However, nonspecific inhibitors of class I and II HDAC lead to a change in eNOS expression. In nonendothelial cells in which eNOS is normally not expressed, inhibition of class I and II HDAC with trichostatin A (TSA), combined with inhibition of DNA methyltransferase activity with 5-aza-2Ј-deoxycytidine resulted in induction of eNOS transcript. 41 In contrast, TSA and butyric acid, another nonspecific HDAC inhibitor, suppressed eNOS protein levels in endothelial cells, and prevented NO-dependent relaxation of coronary arteries. 42 These somewhat contradictory findings hint at a complex role of class I and II HDAC in the regulation of eNOS expression and may reflect the use of nonspecific HDAC inhibitors. The added role of HDAC3 in posttranslational modification of eNOS injects another layer of regulation of eNOS by HDAC, and indicates that specific HDAC may have distinct and perhaps opposing effects on endotheliumdependent vascular functions.
Endothelium-derived NO is not only important in the regulation of vascular tone but also inhibits platelet aggregation and adhesion 43 and suppresses smooth muscle cell proliferation and migration to form the neointima, 44 all of which contribute to the pathological processes of atherosclerosis and thrombosis. Thus, the stimulatory effect of low-dose aspirin on endothelial NO production through lysine acetylation of eNOS, and its antagonism by HDAC3, is likely to have relevance not only to endothelium-dependent regulation of vascular tone but also to atherothrombosis, which results in tissue ischemia and infarction. Therefore, selective inhibition of HDACs may form the basis of adjunctive therapies aimed to improve the efficacy of aspirin in the prevention and treatment of cardiovascular disease and stroke. In addition, epidemiological data indicate that the use of low-dose aspirin also reduces the risk of proliferative disorders, including colorectal and prostate neoplasia. 45, 46 Because HDAC3 plays a part in the molecular pathogenesis of these disorders, 47, 48 aspirin and HDAC3 may also act in an antagonistic fashion to regulate the lysine acetylation status of targets that play a role in neoplastic development.
Although low-dose aspirin is widely used in the prevention and treatment of cardiovascular disease, a significant proportion of patients on aspirin experience atherothrombotic events. The pathophysiological and molecular mechanisms underlying this phenomenon, termed "aspirin resistance," have not been clearly identified. There are likely multiple reasons for this phenomenon. Some that have been proposed include aspirin-insensitive thromboxane A 2 synthesis in platelets, increased collagen sensitivity of platelets, and mutations/polymorphisms in genes involved in the mechanisms of action of aspirin. 49 Suppression of aspirin-induced lysine acetylation and activation of eNOS, and consequent decreased endothelial NO production, could also be an endogenous mechanism responsible for the phenomenon of aspirin resistance. Importantly, HDAC inhibitors are presently under clinical trials for the treatment of solid and hematologic malignancies, 50, 51 raising the possibility that, if HDAC3 is an endogenous antagonist to the salutary effects of aspirin on the endothelium, then specific HDAC3 inhibitors might offer therapeutic benefit when used in combination with aspirin for the treatment and prevention of cardiovascular diseases.
